3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Polycystic Ovary Syndrome
9
Hyperandrogenism
4
Neoplasms
3
Skin Diseases
1
Sarcoma
1
Rare Diseases
1
Obesity
1
Metabolic Syndrome
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Hematologic Neoplasms
1
Heart Failure
1
Glioblastoma
1
Endocrine System Diseases
1
Critical Illness
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Breast Neoplasms
1
Advanced Malignant Neoplasm
1
Acute Kidney Injury
1
Acanthosis Nigricans
1
Interventions
Doxorubicin
15
Exercise
9
Cyclophosphamide
9
Dexrazoxane
8
Razoxane
6
Carvedilol
6
Vincristine
4
Trastuzumab
4
Radiotherapy
4
Filgrastim
4
Docetaxel
4
Methotrexate
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Echocardiography
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Silymarin
2
Prednisone
2
Paclitaxel
2
Neoadjuvant Therapy
2
Leucovorin
2
Ivabradine
2
High-Intensity Interval Training
2
Epirubicin
2
Electrocardiography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cardiotoxicity
×
Spironolactone
×
Clear all
NCT06005259
2023-08-22
SPIROTOX
University of Sao Paulo
Phase 4
Unknown
264 enrolled